Want to see HK:0719 full AI Analyst Report?
Top Page
Shandong Xinhua Pharmaceutical Company Limited Class H
(0719)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$6.50
▼(-2.55% Downside)
Action:Reiterated
Date:09/22/26
The score is driven primarily by weakening financial performance (TTM revenue decline and sharp margin compression) despite a serviceable balance sheet and improving but historically volatile cash generation. Technicals are moderately supportive with price above key moving averages, but momentum signals are mixed (slightly negative MACD and high RSI). Valuation is the main constraint, with a high P/E that looks stretched relative to the recent profitability slowdown, only partly cushioned by a ~2.73% dividend yield.
Positive Factors
Diversified pharmaceutical manufacturing
The company spans APIs, finished medicines, and chemical intermediates, giving it multiple routes to pharmaceutical demand. This vertical breadth can support production flexibility, broaden customer applications, and reduce reliance on a single product category over the next several quarters.
Negative Factors
TTM revenue decline
The latest revenue contraction interrupts the company’s earlier growth trajectory and signals weaker demand or pricing conditions. Sustained top-line pressure would reduce operating leverage, constrain reinvestment, and make recovery in earnings more dependent on cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified pharmaceutical manufacturing
The company spans APIs, finished medicines, and chemical intermediates, giving it multiple routes to pharmaceutical demand. This vertical breadth can support production flexibility, broaden customer applications, and reduce reliance on a single product category over the next several quarters.
Read all positive factors
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$9.68B
Dividend Yield2.97%
Average Volume (3M)1.67M
Price to Earnings (P/E)47.1
Beta (1Y)0.61
Revenue Growth4.81%
EPS Growth-48.21%
CountryHK
Employees7,240
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.31
Shares Outstanding195,000,000
10 Day Avg. Volume2,183,760
30 Day Avg. Volume1,670,500
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)0.78
Price to Sales (P/S)0.47
P/FCF Ratio9.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.81
Revenue Forecast (FY)HK$9.22B
Shandong Xinhua Pharmaceutical Company Limited Class H Business Overview & Revenue Model
Company Description
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic...
How the Company Makes Money
The company makes money primarily by manufacturing and selling (1) APIs, (2) finished pharmaceutical formulations, and (3) chemical intermediates and related chemical products used in pharmaceutical production. Revenue is recognized mainly from pr...
Shandong Xinhua Pharmaceutical Company Limited Class H Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
63
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.44B | 8.75B | 8.47B | 8.10B | 7.50B | 6.56B |
| Gross Profit | 1.50B | 1.64B | 2.04B | 2.32B | 2.04B | 1.77B |
| EBITDA | 437.48M | 988.87M | 1.11B | 1.09B | 1.01B | 908.67M |
| Net Income | 214.48M | 289.89M | 470.02M | 496.51M | 411.06M | 348.55M |
Balance Sheet | ||||||
| Total Assets | 9.13B | 9.19B | 9.02B | 8.29B | 8.27B | 7.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.51B | 1.40B | 1.25B | 918.33M | 1.16B | 744.66M |
| Total Debt | 1.96B | 1.31B | 1.35B | 1.08B | 1.38B | 1.04B |
| Total Liabilities | 3.55B | 3.73B | 3.80B | 3.51B | 3.92B | 3.68B |
| Stockholders Equity | 5.27B | 5.21B | 4.99B | 4.55B | 4.13B | 3.47B |
Cash Flow | ||||||
| Free Cash Flow | 386.47M | 418.13M | 155.19M | -59.85M | 513.48M | 9.89M |
| Operating Cash Flow | 466.13M | 533.73M | 367.61M | 265.28M | 758.24M | 259.12M |
| Investing Cash Flow | -72.51M | -103.50M | -212.21M | -305.11M | -228.90M | -237.69M |
| Financing Cash Flow | -163.67M | -291.13M | 184.78M | -196.11M | -130.66M | -139.73M |
Shandong Xinhua Pharmaceutical Company Limited Class H Technical Analysis
Positive
6.67
Price Trends
5.82
Negative
5.83
Negative
6.16
Negative
Market Momentum
>-0.01
Negative
52.24
Neutral
37.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0719, the sentiment is Positive. The current price of 6.67 is above the 20-day moving average (MA) of 5.69, above the 50-day MA of 5.82, and above the 200-day MA of 6.16, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.24 is Neutral, neither overbought nor oversold. The STOCH value of 37.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0719.
Shandong Xinhua Pharmaceutical Company Limited Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$12.27B | 9.19 | 25.10% | 5.25% | 15.05% | 20.58% | |
69 Neutral | HK$29.21B | 17.41 | 11.97% | 13.29% | -5.90% | -18.84% | |
68 Neutral | HK$27.14B | 5.72 | 7.92% | 5.59% | 7.94% | 52.83% | |
59 Neutral | HK$35.32B | 12.48 | 6.64% | 6.63% | 6.58% | -4.29% | |
55 Neutral | HK$9.68B | 47.14 | 4.10% | 2.97% | 4.81% | -48.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$6.90B | 18.28 | 5.03% | 1.52% | 29.68% | ― |
* Healthcare Sector Average
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
5.81
-1.09
-15.78%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
13.01
-3.95
-23.27%
HK:1513
Livzon Pharmaceutical Group
21.74
-10.97
-33.54%
HK:0460
Sihuan Pharmaceutical Holdings Group
0.72
-1.08
-60.21%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.29
-0.33
-7.12%
HK:1681
Consun Pharmaceutical Group Ltd.
14.85
-1.64
-9.96%
Shandong Xinhua Pharmaceutical Company Limited Class H Corporate Events
Shandong Xinhua Subsidiary Wins Approval for Donepezil Orally Disintegrating Tablets in China
Sep 18, 2026
Shandong Xinhua Pharmaceutical announced that its wholly owned subsidiary, Shandong Zibo Xincat Pharmaceutical, has obtained a drug registration certificate from China’s National Medical Products Administration for its 5mg Donepezil Hydrochl...
Shandong Xinhua Pharmaceutical Wins Approval for New Oral Solution
Sep 18, 2026
Shandong Xinhua Pharmaceutical Company Limited has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its magnesium sulfate, sodium sulfate and potassium sulfate concentrate oral solution, clas...
Shandong Xinhua Pharma Wins Approval for Levocarnitine Oral Solution
Sep 18, 2026
Shandong Xinhua Pharmaceutical Company Limited, a Chinese producer of chemical prescription drugs, has expanded its product portfolio with a new oral formulation. The company focuses on domestic drug production and compliance with national pharmac...
Shandong Xinhua Subsidiary Wins Key Generic Consistency Approval for Azithromycin
Aug 31, 2026
Shandong Xinhua Pharmaceutical has announced that its wholly owned subsidiary, Shandong Zibo Xincat Pharmaceutical, received approval from China’s National Medical Products Administration confirming that its azithromycin tablets have passed ...
Shandong Xinhua Wins NMPA Approval for Dapoxetine Tablets
Aug 28, 2026
Shandong Xinhua Pharmaceutical has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its domestically produced Dapoxetine Hydrochloride Tablets, a Class 4 chemical prescription drug. The appro...
Shandong Xinhua Pharmaceutical Releases Unaudited 2026 Interim Results
Aug 25, 2026
Shandong Xinhua Pharmaceutical Company Limited, a PRC-based drug manufacturer, operates from Zibo City in Shandong Province and is listed on both the Hong Kong and Shenzhen stock exchanges. The company’s dual listing structure in H and A sha...
Xinhua Pharmaceutical Wins China Approval for Dapagliflozin Tablets
Aug 21, 2026
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate from China’s National Medical Products Administration for its dapagliflozin tablets. The approval covers domestically produced 5mg and 10mg prescript...
Shandong Xinhua Pharmaceutical Schedules Board Meeting to Review 2026 Interim Results
Aug 11, 2026
Shandong Xinhua Pharmaceutical Company Limited has scheduled a board meeting to be held at its conference room in Zibo, Shandong, on 25 August 2026. The meeting will review and approve the unaudited interim results for the six months ended 30 June...
Shandong Xinhua Pharmaceutical Declares 2025 Final Dividend and Clarifies Tax Arrangements
Jun 26, 2026
Shandong Xinhua Pharmaceutical Company Limited has declared a final ordinary cash dividend of RMB 0.15 per share for the financial year ended 31 December 2025, with shareholder approval obtained on 26 June 2026. The dividend for H-share investors ...
Shandong Xinhua Pharmaceutical Shareholders Approve All AGM Resolutions and 2025 Dividend Plan
Jun 26, 2026
Shandong Xinhua Pharmaceutical Company Limited reported that all resolutions at its 26 June 2026 annual general meeting in Zibo, Shandong, were approved by shareholders via poll, with participating shares representing about 33.48% of the company&#...
Xinhua Pharmaceutical Wins Approval to Begin Clinical Trials for Novel Pain Drug LXH-2103
Jun 22, 2026
Shandong Xinhua Pharmaceutical Company Limited has received regulatory approval from China’s National Medical Products Administration to commence clinical trials for its LXH-2103 injection, a Class 1 innovative prescription drug. The injecti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.